A detailed history of Caption Management, LLC transactions in Tg Therapeutics, Inc. stock. As of the latest transaction made, Caption Management, LLC holds 30,000 shares of TGTX stock, worth $931,800. This represents 0.01% of its overall portfolio holdings.

Number of Shares
30,000
Holding current value
$931,800
% of portfolio
0.01%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 14, 2023

BUY
$8.36 - $26.5 $278,388 - $882,450
33,300 New
33,300 $278,000
Q1 2023

May 15, 2023

BUY
$10.23 - $19.34 $354,254 - $669,724
34,629 New
34,629 $520,000
Q3 2022

Nov 14, 2022

BUY
$4.57 - $8.4 $1.62 Million - $2.98 Million
355,000 Added 507.14%
425,000 $2.52 Million
Q2 2022

Aug 15, 2022

SELL
$3.74 - $10.66 $2.13 Million - $6.08 Million
-569,900 Reduced 89.06%
70,000 $298,000
Q4 2021

Feb 11, 2022

BUY
$15.2 - $35.51 $9.04 Million - $21.1 Million
594,900 Added 1322.0%
639,900 $12.2 Million
Q3 2021

Nov 12, 2021

BUY
$21.78 - $40.45 $865,755 - $1.61 Million
39,750 Added 757.14%
45,000 $1.5 Million
Q2 2021

Aug 16, 2021

BUY
$32.5 - $48.96 $170,625 - $257,040
5,250 New
5,250 $204,000
Q3 2020

Nov 16, 2020

SELL
$18.49 - $27.24 $162,712 - $239,712
-8,800 Closed
0 $0
Q2 2020

Aug 14, 2020

SELL
$8.9 - $21.84 $322,180 - $790,608
-36,200 Reduced 80.44%
8,800 $172,000
Q1 2020

May 15, 2020

BUY
$7.14 - $15.99 $321,300 - $719,550
45,000 New
45,000 $443,000
Q4 2018

Jan 30, 2019

SELL
$3.44 - $5.76 $71,896 - $120,384
-20,900 Closed
0 $0
Q3 2018

Nov 14, 2018

BUY
$5.15 - $14.0 $107,635 - $292,600
20,900 New
20,900 $117,000

Others Institutions Holding TGTX

About TG THERAPEUTICS, INC.


  • Ticker TGTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 145,274,000
  • Market Cap $4.51B
  • Description
  • TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...
More about TGTX
Track This Portfolio

Track Caption Management, LLC Portfolio

Follow Caption Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Caption Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Caption Management, LLC with notifications on news.